Asco 2023 – Regeneron nips at Bristol’s heels in Lag3
Fianlimab continues to look like biopharma’s leading Lag3 asset, with activity in a new melanoma setting to boot.
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
Novo makes a gene editing move
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Here come the PD-1 agonists
Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?
Scribe signs another big pharma deal
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
ESPID 2023 – hospitalisation data in tune for Beyfortus
The Harmonie trial shows a hospitalisation benefit where Melody could not.
